Bavarian Nordic AS BVNKF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $27.80
- Day Range
- $27.69–27.69
- 52-Week Range
- $27.69–37.22
- Bid/Ask
- $19.02 / $30.50
- Shares Outstanding
- 75.68M
- Market Cap
- $2.12B
- Volume/Avg
- 628 / 485
Key Statistics
- Price/Earnings (Normalized)
- 11.89
- Price/Sales
- 2.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 1.69%
Company Profile
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,861
- Website
- https://www.bavarian-nordic.com
Valuation
|
Metric
|
BVNKF
|
|---|---|
Price/Earnings (Normalized) | 11.89 |
Price/Book Value | 1.10 |
Price/Sales | 2.37 |
Price/Cash Flow | 6.07 |
Price/Earnings
BVNKF
Profitability
|
Metric
|
BVNKF
|
|---|---|
Return on Assets (Normalized) | 8.50% |
Return on Equity (Normalized) | 9.82% |
Return on Invested Capital (Normalized) | 9.51% |
Return on Assets
BVNKF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|K$bW?B | LOCK|p@r# | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|K#!M>H | LOCK|VZ<% | $81B | |||
| argenx SE ADR
ARGX
| LOCK|dDNj!MZ | LOCK|Lm@ | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|kYx@<@k | LOCK|Xc$fN | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#GYhslC | LOCK|KfH | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%>xxV^ | LOCK|zZP%! | $29B | |||
| Incyte Corp
INCY
| LOCK|lZ^@#v | LOCK|^r | $24B | |||
| Moderna Inc
MRNA
| LOCK|#Zy<$Zy | LOCK|d& | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|hL!pV? | LOCK|n<Z | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|rFTK>qz | LOCK|^s | $17B |
United States